Cardiovascular Therapeutics

Cover image for Vol. 33 Issue 3

Edited By: Henry Krum, PhD and Chim C. Lang, MD,

Impact Factor: 2.362

ISI Journal Citation Reports © Ranking: 2014: 57/123 (Cardiac & Cardiovascular Systems); 128/254 (Pharmacology & Pharmacy)

Online ISSN: 1755-5922



Author Guidelines


MANUSCRIPT SUBMISSION

Thank you for your interest in Cardiovascular Therapeutics. Please read the complete Author Guidelines carefully prior to submission, including the section on copyright. To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review.

Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/cdr

Full instructions and support are available on the site and a user ID and password can be obtained on the first visit. For technical support please dial +1 434 817 2040 ext. 167, or via the 'Get Help Now' link in the top right-hand corner of the login screen. If you cannot submit online, please contact the Editorial Office.

We look forward to your submission.

EDITORIAL AND CONTENT CONSIDERATIONS

Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) focuses on extensive reviews and original articles on the pharmacology and pharmacokinetics, toxicology, human investigation and clinical trials of new or potential cardiovascular drugs. Articles in cardiovascular translational research, pharmacogenomics and personalized medicine, gene and cell therapies and pharmacoepidemiology are also encouraged.

EXPEDITED: Publish your clinical trials faster. EXPEDITED is the new priority publication service from Cardiovascular Therapeutics exclusively for well conducted, well reported clinical trials. Priority peer review: 7 working days from online submission. Priority proofs: 7 working days from 'accept' decision. Priority online: 7 working days from proof approval to Early View publication. Priority print: 'Late Breaker' publication in the next print issue. Exclusively for clinical trials (interventional and observational studies). Contact us for more information (CATHedoffice@wiley.com).

EXPEDITED instructions. Step #1 - Apply to the Editorial Office >1 week before online submission with a detailed abstract, list of authors, contributorship statement, clinical trial registration details, clinical trial data posting details (if available), complete CONSORT or STROBE checklist (note: at this stage replace page numbers on this checklist with the word 'Yes' to confirm that each CONSORT/STROBE recommendation has been followed), details of research funding and disclosures of potential conflicts of interest. Step #2 - We will confirm that we have received your application and whether we will expedite your peer review. If we accept your application for the EXPEDITED service, you will receive an invoice for $1,500 (non-refundable). Step #3 - Submit online as an 'EXPEDITED Clinical Trial'. Contact us for more information (CATHedoffice@wiley.com).

EXPEDITED conditions. Standard Cardiovascular Therapeutics peer review processes inform all editorial decisions (see our 'Editorial Policy' pages). The details contained in editorial recommendations and decisions about individual submitted papers are not linked to payment - the EXPEDITED service only aims to deliver these recommendations faster. Clinical trials submitted for consideration via the EXPEDITED service may be rejected. The EXPEDITED service charge is not refundable. Delivery of proofs in 7 working days from 'accept' decision is conditional on transmission of complete and correct copyright paperwork on or before date of 'accept' decision. Proofs will be delivered 7 working days from arrival of transmission of copyright paperwork if copyright paperwork is transmitted later than 'accept' decision. Contact us for more information (CATHedoffice@wiley.com).

ETHICAL CONSIDERATIONS

Research ethics. You will be asked during online submission to confirm that your study has been approved by relevant bodies (e.g. institutional review boards, research ethics committees) and that appropriate consent was obtained for studies involving human participants.

Plagiarism Detection
The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.

Committee on Publication Ethics
The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).

PREPARING YOUR SUBMISSION

Standards. Materials should comply with the ICMJE Uniform Requirements. Manuscripts reporting randomised trials should follow CONSORT guidelines; manuscripts reporting diagnostic accuracy studies should follow STARD guidelines; manuscripts reporting meta-analyses should follow QUOROM guidelines; manuscripts reporting epidemiological studies should follow STROBE guidelines.

Access to data. You will be asked during online submission to confirm that authors had access to the study data that support the publication.

Parts of the Manuscript
The manuscript should be submitted in separate files: title page; main text file; figures.

Title page

Title. Concise and informative title (read Optimizing for Search Engines).

Authors. Names department(s) and institution(s) of all authors. (In online submission system, confirm that all listed authors meet ICMJE authorship criteria and that nobody who qualifies for authorship has been excluded. Credit for authorship should be based on: [1] substantial contributions to research design, or the acquisition, analysis or interpretation of data; [2] drafting the paper or revising it critically; [3] approval of the submitted and final versions. Authors should meet all three criteria.)

Corresponding author. Name, address, email address, telephone and fax numbers. (Corresponding author should take responsibility for communicating with all other authors and getting their approval for the final version to be published. During online submission corresponding authors can nominate an individual, who may or may not be an author, to assist them with administration of the publication process.)

Author contributions. Recommendation: Include a short description of each authors' contribution immediately before your references. (Examples of categories for authors' contributions: Concept/design, Data analysis/interpretation, Drafting article, Critical revision of article, Approval of article, Statistics, Funding secured by, Data collection, Other.)

Main text
As papers are double-blind peer reviewed the main text file should not include any information that might identify the authors. The main text of the manuscript should be presented in the following order: (i) abstract and key words, (ii) text, (iii) references, (iv) tables (each table complete with title and footnotes), (v) appendices, (vii) figure legends. Figures and supporting information should be submitted as separate files.

Research papers. Your manuscript text should not exceed 3,000 words, with a structured abstract (e.g. Aims, Methods, Results, Discussion, Conclusion) of no more than 250 words, a maximum of 5 tables and/or figures, and up to 100 references. Manuscripts that do not meet these criteria will be returned to the authors for revision prior to formal consideration.

Authors of research papers are asked at the point of submission to state their preference for print-and-online publication or online-only publication, in the event that their paper is accepted. As with all articles published in Cardiovascular Therapeutics, articles published online-only are fully citable and indexed. All articles published online-only will be included in the table of contents of the accompanying print issue.

Review papers. Your manuscript text should not exceed 3,000 words, with a structured abstract (e.g. Background, Methods, Results, Conclusion) of no more than 250 words, a maximum of 5 tables and/or figures, and up to 100 references. Manuscripts that do not meet these criteria will be returned to the authors for revision prior to formal consideration.

Funding. Financial support for the study or the manuscript must be disclosed, regardless of its source, including a short description of involvement of the funder in study design, data collection, data analysis, manuscript preparation and/or publication decisions. If none, state "none".

Acknowledgements. Nonfinancial support (e.g. donations of drugs or devices) and individuals who contributed to the study or the manuscript but do not quality as authors must be acknowledged. If none, state "none".

Disclosures. Each author must disclose all financial relationships for the previous 12 months, whether or not they are related to the subject of the paper. This should include equity ownership, profit-sharing agreements, royalties, patents, and grants. Income from pharmaceutical companies should be specified by type, e.g. speaker's honoraria, expenses, grants, etc. Authors do not need to report the sums concerned. If none, state "none".

Prior Publication. You will be asked during online submission to confirm that the submitted work is not published, in press or currently being considered for publication elsewhere. (Abstracts, presentations at scientific meetings and clinical trial data posting should be indicated in your cover letter. Publication of abstracts, presentations at scientific meetings and subsequent press coverage will not jeopardize full publication in Cardiovascular Therapeutics. Posting of clinical trials results in databases [data without interpretation, discussion, context or full conclusions in the form of tables and text to describe data/information where this is not easily presented in tabular form] prior to submission to Cardiovascular Therapeutics will not jeopardize full peer reviewed publication in the journal).

Measurements, abbreviations, drug names. Measurements should be given in the units in which they were made, but non-metric units must be accompanied by metric (SI) equivalents (exceptions: blood pressure in mmHg; haemoglobin in g/dl). Generic drug names should be used (drug brand names must not be used). If an acronym is used, the term for which it stands should be given in full at its first mention in the text, for example, anti-diuretic hormone (ADH).

Clinical trials - registration. Reports of clinical trials should include the clinical trial registration number and registry name at the end of the abstract.

Clinical trials - data posting. If trial data are posted online before submission and peer reviewed publication, provide the clinical trial results database number and database name at the end of your abstract.

References. Original textual matter quoted from other authors must have formal citation and be appropriately attributed and referenced. Authors should verify references against the original documents. References should be identified in the text using square brackets, and numbered and listed consecutively at the end of the paper in the order in which they are first cited in the text. The Vancouver style is used.

Journals. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM. Apoptosis in human acute myocardial infarction. Circulation 1997;95:320-333.

Books. Czarnetzki BM. Urticaria. Berlin: Springer, 1986.

Chapter in book. Clissold SP. Rhinitis. In: Barnes PJ, Mygind N, editors. Budesonide: clinical experience in asthma and rhinitis. Manchester: ADIS Press, 1988;51-64.

Appendix (e.g. list of participating physicians). Optional. Will appear in print and online. Use an appendix immediately following references to list further details related to clinical studies like participating physicians, clinical and coordinating centers (which should be presented in the most concise form possible, i.e. not tabulated).

Tables. All tables should be mentioned in the text and individually numbered. Tables should be presented together and separated from the main text. They should be numbered in the order in which they are mentioned in the text, and each should have a short explanatory caption. Each table column should have a short heading. Any tables previously published should include an acknowledgement in the caption, and the full reference included in the reference list.

Figure legends
Type figure legends on a separate page. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement. Staining techniques and the magnification of micrographs should be stated.

Figures
All illustrations (line drawings and photographs) are classified as figures. Only those essential to the paper should be included. Figures should be numbered using Arabic numerals, and cited in consecutive order in the text. If the subjects of photographs are identifiable, either their eyes should be masked or their written permission to use the photograph be submitted with the manuscript. Any information (including personal data) that could enable a patient to be identified should be removed. Any illustrations and figures previously published should include an acknowledgement in the caption, and the full reference included in the list.

Preparation of Electronic Figures for Publication: Although low quality images are adequate for review purposes, publication requires high quality images to prevent the final product being blurred or fuzzy. Advice on figures can be found at Wiley’s guidelines for preparation of figures: http://authorservices.wiley.com/bauthor/illustration.asp

Supporting Information
Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found at: http://authorservices.wiley.com/bauthor/suppmat.asp.

Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.

SUBMISSION REQUIREMENTS

Manuscripts should be submitted online at https://mc.manuscriptcentral.com/cdr

• A cover letter containing an authorship statement should be included in the ‘Cover Letter Field’ of the ScholarOne system. The text can be entered directly into the field or uploaded as a file. Your cover letter should include the following: (i) an explanation about why your manuscript is suitable for publication in Cardiovascular Therapeutics; and (ii) an indication of whether the research has been published before as an abstract, presented at a scientific meeting, or published in a clinical trial data posting. Note this will not jeopardize full peer reviewed publication in the journal).

• Two Word-files need to be included upon submission: A title page file and a main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.

• The main text file should be prepared using Microsoft Word, doubled-spaced.

• Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files will be required.

PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licencing options for the journal appear below.

Wiley’s Author Services

Author Services enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://www.authorservices.wiley.com/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Accepted Articles

The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. After print publication, the DOI remains valid and can continue to be used to cite and access the article. The Accepted Articles service has been designed to ensure the earliest possible circulation of research papers after acceptance. Given that copyright licensing is a condition of publication, a completed copyright form is required before a manuscript can be processed as an Accepted Article. Accepted articles will be indexed by PubMed; therefore the submitting author must carefully check the names and affiliations of all authors provided in the cover page of the manuscript, as it will not be possible to alter these once a paper is made available online in Accepted Article format. Subsequently the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will automatically be updated.

Proofs

Once the paper has been typeset the corresponding author will receive an e-mail alert containing instructions on how to provide proof corrections to the article. It is therefore essential that a working e-mail address is provided for the corresponding author. Proofs should be corrected carefully; the responsibility for detecting errors lies with the author. The proof should be checked, and approval to publish the article should be emailed to the Publisher by the date indicated; otherwise, it may be signed off on by the Editor or held over to the next issue.

Early View

The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.

Offprints

A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: http://offprint.cosprinters.com/cos. If you have queries about offprints please e-mail: offprint@cosprinters.com.

Author Marketing Toolkit

The Wiley Author Marketing Toolkit provide authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.

COPYRIGHT, LICENSING AND ONLINE OPEN

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.

Authors may choose to publish under the terms of the journal’s standard copyright transfer agreement (CTA), or under open access terms made available via Wiley OnlineOpen.

Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard CTA in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at: Copyright Terms and Conditions FAQs.

Note that in signing the journal’s licence agreement authors agree that consent to reproduce figures from another source has been obtained.

OnlineOpen – Wiley’s Open Access Option: OnlineOpen is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons license. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made open access. Authors of OnlineOpen articles are permitted to post the final, published PDF of their article on their personal website, and in an institutional repository or other free public server immediately after publication. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

OnlineOpen licenses. Authors choosing OnlineOpen retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the terms and conditions of these open access agreements please visit the Copyright Terms and Conditions FAQs.

Funder Open Access and Self-Archiving Compliance: Please click here for more information on Wiley’s compliance with specific Funder Open Access and Self Archiving Policies, and click here for more detailed information specifically about Self-Archiving definitions and policies.

PUBLICATION FORMAT

Cardiovascular Therapeutics is published in electronic format only.

Author Guidelines updated 910June 2015

SEARCH

SEARCH BY CITATION